Ascendis Pharma A/S

NasdaqGS ASND

Ascendis Pharma A/S Market Capitalization on January 14, 2025: USD 7.87 B

Ascendis Pharma A/S Market Capitalization is USD 7.87 B on January 14, 2025, a -0.57% change year over year. Market capitalization represents total company value in stock market; higher suggests larger, more established company.

Ascendis Pharma A/S 52-week high Market Capitalization is USD 9.45 B on February 23, 2024, which is 20.08% above the current Market Capitalization.
Ascendis Pharma A/S 52-week low Market Capitalization is USD 6.75 B on September 11, 2024, which is -14.24% below the current Market Capitalization.
Ascendis Pharma A/S average Market Capitalization for the last 52 weeks is USD 8.11 B.

Key data

Date	Market Capitalization	Share Price	Price to Earnings Ratio (P/E)	Price to Sales Ratio (P/S)

NasdaqGS: ASND

Ascendis Pharma A/S

CEO	Mr. Jan Moller Mikkelsen
IPO Date	Jan. 28, 2015
Location	Denmark
Headquarters	Tuborg Boulevard 12
Employees	879
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Key trends

Past 5 years